# Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

> **NCT00553306** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **BIOLOGICAL:** aldesleukin
- **DRUG:** cyclophosphamide
- **PROCEDURE:** biopsy
- **OTHER:** immunohistochemistry staining method
- **OTHER:** flow cytometry
- **GENETIC:** polymerase chain reaction

## Key facts

- **NCT ID:** NCT00553306
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-08
- **Final completion:** 2012-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553306, "Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00553306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*